Cargando…
Eprosartan improves cardiac function in swine working heart model of ischemia-reperfusion injury
BACKGROUND: Eprosartan is an angiotensin II receptor antagonist used as an antihypertensive. We sought to evaluate the regional effect of Eprosartan on postinfarct ventricular remodeling and myocardial function in an isolated swine working heart model of ischemia-reperfusion injury. MATERIAL/METHODS...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010602/ https://www.ncbi.nlm.nih.gov/pubmed/24762635 http://dx.doi.org/10.12659/MSMBR.890444 |
_version_ | 1782479880279031808 |
---|---|
author | Weymann, Alexander Sabashnikov, Anton Patil, Nikhil P. Konertz, Wolfgang Modersohn, Diethelm Dohmen, Pascal M. |
author_facet | Weymann, Alexander Sabashnikov, Anton Patil, Nikhil P. Konertz, Wolfgang Modersohn, Diethelm Dohmen, Pascal M. |
author_sort | Weymann, Alexander |
collection | PubMed |
description | BACKGROUND: Eprosartan is an angiotensin II receptor antagonist used as an antihypertensive. We sought to evaluate the regional effect of Eprosartan on postinfarct ventricular remodeling and myocardial function in an isolated swine working heart model of ischemia-reperfusion injury. MATERIAL/METHODS: 22 swine hearts were perfused with the Langendorff perfusion apparatus under standard experimental conditions. Myocardial ischemia was induced by a 10-min left anterior descending artery ligation. Hearts were reperfused with either saline (control group, n=11), or Eprosartan (treatment group, n=11). Left ventricular pressure (LVP) and regional heart parameters such as intramyocardial pressure (IMP), wall thickening rate (WTh), and pressure-length-loops (PLL) were measured at baseline and after 30 min of reperfusion. RESULTS: Measured parameters were statistically similar between the 2 groups at baseline. The administration of Eprosartan led to a significantly better recovery of IMP and WTh: 44.4±2.5 mmHg vs. 51.2±3.3 mmHg, p<0.001 and 3.8±0.4 μm vs. 4.4±0.3 μm, p=0.001, respectively. PLL were also significantly higher in the treatment group following reperfusion (21694±3259 units vs. 31267±3429 units, p<0.01). There was no difference in the LVP response to Eprosartan versus controls (63.6±3.0 mmHg vs. 62.5±3.1 mmHg, p=0.400). CONCLUSIONS: Pre-treatment with Eprosartan is associated with a significant improvement in regional cardiac function under ischemic conditions. Pharmacological treatment with eprosartan may exert a direct cardioprotective effect on ischemic myocardium. |
format | Online Article Text |
id | pubmed-4010602 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-40106022014-05-06 Eprosartan improves cardiac function in swine working heart model of ischemia-reperfusion injury Weymann, Alexander Sabashnikov, Anton Patil, Nikhil P. Konertz, Wolfgang Modersohn, Diethelm Dohmen, Pascal M. Med Sci Monit Basic Res Animal Studies BACKGROUND: Eprosartan is an angiotensin II receptor antagonist used as an antihypertensive. We sought to evaluate the regional effect of Eprosartan on postinfarct ventricular remodeling and myocardial function in an isolated swine working heart model of ischemia-reperfusion injury. MATERIAL/METHODS: 22 swine hearts were perfused with the Langendorff perfusion apparatus under standard experimental conditions. Myocardial ischemia was induced by a 10-min left anterior descending artery ligation. Hearts were reperfused with either saline (control group, n=11), or Eprosartan (treatment group, n=11). Left ventricular pressure (LVP) and regional heart parameters such as intramyocardial pressure (IMP), wall thickening rate (WTh), and pressure-length-loops (PLL) were measured at baseline and after 30 min of reperfusion. RESULTS: Measured parameters were statistically similar between the 2 groups at baseline. The administration of Eprosartan led to a significantly better recovery of IMP and WTh: 44.4±2.5 mmHg vs. 51.2±3.3 mmHg, p<0.001 and 3.8±0.4 μm vs. 4.4±0.3 μm, p=0.001, respectively. PLL were also significantly higher in the treatment group following reperfusion (21694±3259 units vs. 31267±3429 units, p<0.01). There was no difference in the LVP response to Eprosartan versus controls (63.6±3.0 mmHg vs. 62.5±3.1 mmHg, p=0.400). CONCLUSIONS: Pre-treatment with Eprosartan is associated with a significant improvement in regional cardiac function under ischemic conditions. Pharmacological treatment with eprosartan may exert a direct cardioprotective effect on ischemic myocardium. International Scientific Literature, Inc. 2014-04-25 /pmc/articles/PMC4010602/ /pubmed/24762635 http://dx.doi.org/10.12659/MSMBR.890444 Text en © Med Sci Monit, 2014 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License |
spellingShingle | Animal Studies Weymann, Alexander Sabashnikov, Anton Patil, Nikhil P. Konertz, Wolfgang Modersohn, Diethelm Dohmen, Pascal M. Eprosartan improves cardiac function in swine working heart model of ischemia-reperfusion injury |
title | Eprosartan improves cardiac function in swine working heart model of ischemia-reperfusion injury |
title_full | Eprosartan improves cardiac function in swine working heart model of ischemia-reperfusion injury |
title_fullStr | Eprosartan improves cardiac function in swine working heart model of ischemia-reperfusion injury |
title_full_unstemmed | Eprosartan improves cardiac function in swine working heart model of ischemia-reperfusion injury |
title_short | Eprosartan improves cardiac function in swine working heart model of ischemia-reperfusion injury |
title_sort | eprosartan improves cardiac function in swine working heart model of ischemia-reperfusion injury |
topic | Animal Studies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010602/ https://www.ncbi.nlm.nih.gov/pubmed/24762635 http://dx.doi.org/10.12659/MSMBR.890444 |
work_keys_str_mv | AT weymannalexander eprosartanimprovescardiacfunctioninswineworkingheartmodelofischemiareperfusioninjury AT sabashnikovanton eprosartanimprovescardiacfunctioninswineworkingheartmodelofischemiareperfusioninjury AT patilnikhilp eprosartanimprovescardiacfunctioninswineworkingheartmodelofischemiareperfusioninjury AT konertzwolfgang eprosartanimprovescardiacfunctioninswineworkingheartmodelofischemiareperfusioninjury AT modersohndiethelm eprosartanimprovescardiacfunctioninswineworkingheartmodelofischemiareperfusioninjury AT dohmenpascalm eprosartanimprovescardiacfunctioninswineworkingheartmodelofischemiareperfusioninjury |